ELISA – News and Features
News
Bt maize not harmful to ladybirds
Genetically modified maize has no harmful impacts on the two-spotted ladybird.
News
VaxGen and diaDexus Complete Merger
VaxGen issues approximately 19,960,534 shares to certain diaDexus stockholders and officers.
News
Precision Antibody Selected to Provide Antibody Characterization for National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative
Second contract awarded to company as part of NCI initiative to improve monoclonal antibody reagents for proteomics research.
News
Warnex, MHI and CEPMed Collaborate to Develop a new Diagnostic Test for Cadiovascular and Metabolic Diseases
New test is believed to enable more personalized treatment of diseases such as atherosclerosis and diabetes.
News
Thermo Fisher Scientific and Intrinsic Bioprobes Collaborate to Develop MS Immunoassay Workflow
Turnkey MSIA solution allows researchers to differentiate and quantitate low-abundance intact proteins and their variants.
News
2BScientific and Symansis Announce Marketing and Logistics Collaboration
Agreement covers European distribution and logistic centre including co-marketing of Symansis products in Europe.
News
BioGenes Says Generic HCP Assays Provide Insufficient Sensitivity
Study suggests that continued use of generic HCP assays may lead to insufficient process documentation and finally to safety hazards for patients.
News
Molecular Devices Launches New Products & Customer-Focused Brand at Society for Biomolecular Sciences Meeting
New IonWorks Barracuda™ Automated High-Speed Patch Clamp System & AquaMax® 2000/4000 Microplate Washer 96 Cell-Wash Head
News
Gyros platform enters leading US Clinical Research Organization
CEDRA Corporation, a division of Worldwide Clinical Trials, invests in Gyrolab workstation
News
Precision Antibody Wins Contract to Develop “Gold Standard” Antibodies as Part of National Cancer Institute’s Clinical Proteomics Technologies for Cancer (CPTC) Initiative
Precision Antibody™ has been selected as the antibody developer for a component of the National Cancer Institute (NCI)’s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.
Advertisement
